Where does Viking Therapeutics's income statement data come from?

Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$0—	$0—	$0—	$0—	$0—
Research and development	$453.72M+31.5%	$344.96M+55.0%	$222.48M+43.2%	$155.32M+30.6%	$118.93M+17.0%
General and administrative	$48.28M-0.2%	$48.39M-7.6%	$52.36M-9.0%	$57.52M+7.7%	$53.39M+8.3%
Other operating expenses	$502M+27.6%	$393.34M+43.1%	$274.84M+29.1%	$212.84M+23.5%	$172.32M+14.2%
Total operating expenses	$502M+27.6%	$393.34M+43.1%	$274.84M+29.1%	$212.84M+23.5%	$172.32M+14.2%
Operating income	-$502M-27.6%	-$393.34M-43.1%	-$274.84M-29.1%	-$212.84M-23.5%	-$172.32M-14.2%
Interest expense	$29.64M-12.1%	$33.7M-10.2%	$37.51M-9.1%	$41.27M-6.3%	$44.06M+7.6%
Other income (expense), net	$29.66M-12.0%	$33.7M-10.0%	$37.45M-9.3%	$41.29M-6.3%	$44.08M+7.6%
Net investment gains (losses)	——	$55K+30.2%	$42.25K-69.3%	$137.5K+9.3%	$125.75K+12.3%
Net income	-$472.34M-31.3%	-$359.64M-51.5%	-$237.39M-38.4%	-$171.55M-33.8%	-$128.24M-16.6%
Diluted earnings per share	-$4.15-30.1%	-$3.19-50.5%	-$2.12-38.6%	-$1.53-33.0%	-$1.15-15.0%
Basic earnings per share	-$4.15-30.1%	-$3.19-50.5%	-$2.12-38.6%	-$1.53-33.0%	-$1.15-15.0%
Weighted-average shares, diluted	452.7M+0.8%	449.2M+0.8%	445.6M+0.3%	444.2M+0.4%	442.4M+2.0%
Weighted-average shares, basic	452.7M+0.8%	449.2M+0.8%	445.6M+0.3%	444.2M+0.4%	442.4M+2.0%
Interest Income (Expense), Nonoperating	$29.64M-12.1%	$33.7M-10.2%	$37.51M-9.1%	$41.27M-6.3%	$44.06M+7.6%
Amortization Of Financing Costs Equity Transactions	$32K-42.9%	$56K-30.0%	$80K-16.7%	$96K+6.7%	$90K-4.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$472.98M-31.9%	-$358.47M-50.2%	-$238.65M-40.8%	-$169.44M-33.6%	-$126.85M-14.9%
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	$54K+14.9%	$47K+135%	-$135K-1.5%	-$133K-1.5%	-$131K+41.8%
Net unrealized gains (losses) on securities still held	-$684K-161%	$1.13M+201%	-$1.12M-150%	$2.24M+47.9%	$1.51M+970%
Other income, net (Note 6)	$29.66M-12.0%	$33.7M-10.0%	$37.45M-9.3%	$41.29M-6.3%	$44.08M+7.6%
Revenue From Contract With Customer Excluding Assessed Tax	$0—	$0—	$0—	$0—	$0—
EBIT	-$502M-27.6%	-$393.34M-43.1%	-$274.84M-29.1%	-$212.84M-23.5%	-$172.32M-14.2%
EBIT	-$502M-27.6%	-$393.34M-43.1%	-$274.84M-29.1%	-$212.84M-23.5%	-$172.32M-14.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Viking Therapeutics's income statement data come from?: Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.